文献速递鼻科

过敏检测方法对免疫治疗结局的比较效果

Comparative effectiveness of allergy testing method in driving immunotherapy outcomes.
PubMed 文献 · Int Forum Allergy Rhinol · 2017-12-20

本研究比较了皮肤点刺试验(SPT)、体外检测(IVT)和皮内稀释试验(IDT)指导免疫治疗的效果。177例患者中90例达到维持期,IDT的达维持时间(TTM)短于IVT(高反应者HR=2.12,p=0.03),但与SPT无显著差异;RQLQ改善在各方法间无显著差异(p=0.60)。

要点

  • IDT达维持治疗快于IVT,但与SPT无差异
  • 各检测方法间症状改善(RQLQ变化)无显著差异
  • IDT成本62.66美元,增量成本效果比为每缩短一天TTM 0.23美元

核心结论

  • IDT较IVT更快达到维持免疫治疗,但与SPT无差异。
  • TTM与各检测方法间患者症状改善不相关。

研究设计与样本

  • 回顾性比较三种过敏检测方案指导免疫治疗结局的研究,共177例患者(SPT n=40;IVT n=91;IDT n=46)。
  • 采用机构计费数据进行成本分析,并以RQLQ评估维持治疗前后症状。

主要发现

  • 177例中115例为高反应者(SPT n=35;IVT n=39;IDT n=41)。
  • 90例达到维持治疗(SPT n=17;IVT n=37;IDT n=36),其中58例为高反应者(SPT n=15;IVT n=12;IDT n=31)。
  • SPT、IVT、IDT中位TTM分别为542、329、578.5天。
  • IDT较IVT总体及高反应者TTM更短(HR=1.91,p=0.02;HR=2.12,p=0.03),与SPT高反应者相比无统计学意义(p=0.33)。
  • SPT、IVT、IDT组RQLQ中位变化分别为6.5、1、1.5,无统计学意义(p=0.60)。

关键数值与推荐

  • IDT成本为62.66美元,增量成本效果比为每缩短一天TTM 0.23美元。

临床怎么用

  • 选择过敏检测方法时可考虑IDT可能缩短达维持治疗时间,但需权衡其成本。
  • 检测方法选择对症状改善的预期影响有限,应结合临床综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Skin-prick testing (SPT), in vitro testing (IVT), and intradermal-dilutional testing (IDT) are methods to detect patient sensitivities to specific allergens and direct immunotherapy dosing. We used objective and subjective measures of improvement to compare outcomes based on test method. METHODS: Patients underwent 1 of 3 protocols: SPT, screening SPT followed by IDT, or IVT. We used institution billing data to do a cost analysis of these tests. The time to maintenance (TTM) therapy was analyzed and patients were stratified into high and low reactors. The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was used to quantify symptoms pre-maintenance and post-maintenance. RESULTS: Of 177 patients (SPT, n = 40; IVT, n = 91; IDT, n = 46), 115 (SPT, n = 35; IVT, n = 39; IDT, n = 41) were high reactors. Out of 90 patients (SPT, n = 17; IVT, n = 37; IDT, n = 36) reaching maintenance, 58 were high reactors (SPT, n = 15; IVT, n = 12; IDT, n = 31). Overall, SPT, IVT, and IDT median TTM were 542, 329, and 578.5 days, respectively. IDT TTM was shorter compared to IVT overall and in high reactors (hazard ratio [HR] = 1.91, p = 0.02; HR = 2.12, p = 0.03), but was not significant compared to SPT high reactors (p = 0.33). The IDT cost was $62.66, translating to an incremental cost-effectiveness ratio of $0.23 per day of shortened TTM. Median RQLQ change for the SPT, IVT, and IDT groups was 6.5, 1, and 1.5, respectively, but was not significant (p = 0.60). CONCLUSION: IDT reached maintenance immunotherapy quicker than IVT but there was no difference compared to SPT. TTM did not correlate with improvements in patient symptoms between testing methods. This study represents a novel comparison of outcomes based on initial allergy testing method.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Kaffenberger TM, Dedhia RC, Schwarzbach HL, et al. Comparative effectiveness of allergy testing method in driving immunotherapy outcomes. Int Forum Allergy Rhinol. 2017. PMID: 29266815. doi:10.1002/alr.22061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。